Yunnan Baiyao Group Co Ltd
SZSE:000538

Watchlist Manager
Yunnan Baiyao Group Co Ltd Logo
Yunnan Baiyao Group Co Ltd
SZSE:000538
Watchlist
Price: 58.08 CNY -2.44% Market Closed
Market Cap: 102.8B CNY
Have any thoughts about
Yunnan Baiyao Group Co Ltd?
Write Note

Yunnan Baiyao Group Co Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Yunnan Baiyao Group Co Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Yunnan Baiyao Group Co Ltd
SZSE:000538
Retained Earnings
ÂĄ20.1B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
10%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Retained Earnings
ÂĄ11.7B
CAGR 3-Years
36%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Retained Earnings
ÂĄ11.9B
CAGR 3-Years
22%
CAGR 5-Years
24%
CAGR 10-Years
26%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Retained Earnings
ÂĄ34.3B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
20%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Retained Earnings
ÂĄ1.8B
CAGR 3-Years
4%
CAGR 5-Years
11%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Retained Earnings
-ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Yunnan Baiyao Group Co Ltd
Glance View

Market Cap
103.6B CNY
Industry
Pharmaceuticals

Yunnan Baiyao Group Co Ltd is a well-established Chinese healthcare company renowned for its pioneering products in traditional Chinese medicine, particularly in wound care and pain management. With a rich history dating back to 1902, the company originally gained fame for its unique powder that promotes blood circulation and aids in healing. Over the years, Yunnan Baiyao has evolved into a comprehensive healthcare provider, offering a diverse range of products that span over-the-counter medications, personal care items, and even high-tech medical devices. Its commitment to innovation, backed by a robust research and development framework, has positioned it as a leader in the market, appealing to both traditional and modern healthcare consumers. From an investment standpoint, Yunnan Baiyao stands out as a compelling opportunity due to its strong brand recognition and growing market share in a rapidly expanding healthcare sector. The company consistently showcases impressive financial performance, characterized by robust revenue growth and sustainable profit margins. With the rising demand for effective treatment options fueled by an aging population and increasing health awareness in China, Yunnan Baiyao is strategically positioned to capture this opportunity. As it continues to diversify its product lines and expand internationally, investors may find Yunnan Baiyao to be a promising company that embodies the principles of resilience and adaptability, traits that Warren Buffett and Charlie Munger have long advocated in value investing.

Intrinsic Value
67.17 CNY
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Yunnan Baiyao Group Co Ltd's Retained Earnings?
Retained Earnings
20.1B CNY

Based on the financial report for Jun 30, 2024, Yunnan Baiyao Group Co Ltd's Retained Earnings amounts to 20.1B CNY.

What is Yunnan Baiyao Group Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
10%

Over the last year, the Retained Earnings growth was 4%. The average annual Retained Earnings growth rates for Yunnan Baiyao Group Co Ltd have been 4% over the past three years , 3% over the past five years , and 10% over the past ten years .

Back to Top